Test Price
2,800 AED✅ Home Collection Available
MYH9 Gene (DFNA17) Autosomal Dominant Nonsyndromic Hearing Loss — Genetic Test in UAE | 2800 AED | DHA Licensed
Executive Summary & Core Metrics
✅ Accuracy Guarantee
99.9% Diagnostic Sensitivity achieved via ISO-accredited NGS with Sanger confirmation.
✅ Premium Logistics
VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection available daily from 8 AM to 11 PM.
✅ Clinical Guidance
Telephonic post‑test clinical guidance to help you understand your results in the context of audiological findings.
✅ Insurance & Billing
Direct billing verification via WhatsApp: +971 54 548 8731
Test Overview & Methodology
This test screens the entire coding region of the MYH9 gene using Next‑Generation Sequencing (NGS) to detect pathogenic variants responsible for autosomal dominant nonsyndromic hearing loss (DFNA17).
Our Test vs. Closest Alternative
| Feature | Our MYH9 NGS Test | Single‑Gene Sanger Sequencing |
|---|---|---|
| Method | NGS + Sanger Confirmation | Sanger only |
| Diagnostic Yield | >99% for DFNA17 variants | ~95% (may miss rare variants) |
| Turnaround Time | 3–4 weeks | 4–6 weeks |
| Sample Types | Blood, DNA, FTA card | Blood or DNA only |
| Price (AED) | 2800 | Varies (~2500–3200) |
Physician Insight & Safety Protocols
“As a clinical geneticist, I understand the profound emotional impact of a hereditary hearing loss diagnosis. This test delivers highly accurate molecular data, but it must be interpreted alongside comprehensive audiological evaluation and family history. Genetic counseling is strongly recommended before and after testing.”
— Lina Osama Zaki Quteineh, Consultant Medical Genetics (DHA Registration ID: 9294403)
Advisory & Clinical Guidance
This genetic test is a diagnostic aid. It does not replace clinical management of existing hearing loss or associated conditions. Always discuss your results with a qualified healthcare professional before making any treatment or family-planning decisions.
Exclusion Criteria & Emergency Red Flags
- Exclusion Criteria: Individuals without documented sensorineural hearing loss or family history consistent with DFNA17; patients for whom blood draw is contraindicated (severe coagulopathy).
- ER Red Flags: Sudden severe hearing loss, acute vertigo, or focal neurological signs require immediate emergency evaluation — genetic testing should not be prioritized in acute settings.
- Pre‑test Information: Provide a detailed clinical history and a pedigree chart prepared during a genetic counselling session. No fasting or medication adjustments required. All sample collection must be performed by licensed phlebotomists following DHA/MOHAP guidelines.
Patient FAQ & Clinical Guidance
1. What is the MYH9 gene test for deafness?
The MYH9 gene DNA test identifies pathogenic variants causing autosomal dominant non‑syndromic sensorineural hearing loss (DFNA17), enabling accurate diagnosis, prognosis, and genetic counseling for affected families.
2. How is the MYH9 gene DNA test performed?
A small blood sample (or DNA extracted from blood or an FTA card) is collected by a DHA-licensed phlebotomist and sent to our ISO-certified laboratory for NGS analysis, with results returned in 3 to 4 weeks.
3. Are there any risks or special preparations required?
The test is non‑invasive (blood draw) and requires no fasting or medication changes; however, a pre‑genetic counseling session is strongly recommended to explain the implications of the result.
UAE Regulatory & Data Privacy Adherence
All services comply with the following UAE legal frameworks:
- Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL)
- Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields
- Federal Decree-Law No. 4 of 2016 on Medical Liability
ISO 9001:2015 Certified. DHA Facility License: 1143. DNA Labs UAE operates under the regulatory oversight of the Dubai Health Authority.
Clinical & Logistical Metadata
| Test Name | MYH9 Gene (DFNA17) Autosomal Dominant Nonsyndromic Hearing Loss – Genetic Test |
| Price (AED) | 2,800 |
| Turnaround Time | 3–4 weeks |
| Sample Type / Matrix | Peripheral blood, DNA, FTA card |
| Methodology Used | Next-Generation Sequencing (NGS) with Sanger confirmation |
| ICD-10-CM Code | H90.5 (Sensorineural hearing loss, unspecified) |
| LOINC Code | 60591-5 (MYH9 gene mutation analysis) |
| DHA Facility License & Address | License 1143 – Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians